 |
인쇄하기
취소
|
Green Cross' phase II studies for anti-osteoporosis drug successful.
Green Cross announced that a new anti-osteoporosis drug, rhPTH (recombinant human parathyroid hormone) had completed its phase II studies successfully in Germany.
Its pre-clinical and phase I study had been successfully made in England and the U. S. in conformance with the U. S. FDA. Now, it shows a high possibility for its phase III study to be also favorably succeeded.
Prof. Scherbaum...
Its pre-clinical and phase I study had been successfully made in England and the U. S. in conformance with the U. S. FDA. Now, it shows a high possibility for its phase III study to be also favorably succeeded.
Prof. Scherbaum...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.